36 related articles for article (PubMed ID: 22023368)
1. Assessment of Stem Cell Transplant Eligibility in Recipients with Oral Foci of Infection: Appropriate Conditioning Regimens.
Boga C; Sisli SN; Bahar AR; Tamer Y; Kasar M; Bascil S; Ozdogu H; Asma S; Demiroglu YZ; Yeral M
Exp Clin Transplant; 2023 Aug; 21(8):691-700. PubMed ID: 37341460
[TBL] [Abstract][Full Text] [Related]
2. Patients Undergoing Myeloablative Chemotherapy and Hematopoietic Stem Cell Transplantation Exhibit Depleted Vitamin C Status in Association with Febrile Neutropenia.
Carr AC; Spencer E; Das A; Meijer N; Lauren C; MacPherson S; Chambers ST
Nutrients; 2020 Jun; 12(6):. PubMed ID: 32599718
[TBL] [Abstract][Full Text] [Related]
3. Incidence, risk factors, and outcome of bloodstream infections during the pre-engraftment phase in 521 allogeneic hematopoietic stem cell transplantations.
Blennow O; Ljungman P; Sparrelid E; Mattsson J; Remberger M
Transpl Infect Dis; 2014 Feb; 16(1):106-14. PubMed ID: 24372809
[TBL] [Abstract][Full Text] [Related]
4. Application of big data analyses to compare the impact of oral and gastrointestinal mucositis on risks and outcomes of febrile neutropenia and septicemia among patients hospitalized for the treatment of leukemia or multiple myeloma.
Satheeshkumar PS; Blijlevens N; Sonis ST
Support Care Cancer; 2023 Mar; 31(3):199. PubMed ID: 36869162
[TBL] [Abstract][Full Text] [Related]
5. Increased overall and bacterial infections following myeloablative allogeneic HCT for patients with AML in CR1.
Ustun C; Kim S; Chen M; Beitinjaneh AM; Brown VI; Dahi PB; Daly A; Diaz MA; Freytes CO; Ganguly S; Hashmi S; Hildebrandt GC; Lazarus HM; Nishihori T; Olsson RF; Page KM; Papanicolaou G; Saad A; Seo S; William BM; Wingard JR; Wirk B; Yared JA; Perales MA; Auletta JJ; Komanduri KV; Lindemans CA; Riches ML
Blood Adv; 2019 Sep; 3(17):2525-2536. PubMed ID: 31471322
[TBL] [Abstract][Full Text] [Related]
6. [Epidemiology of febrile neutropenia in patients with hematological disease-a prospective multicentre survey in China].
Yan CH; Xu T; Zheng XY; Sun J; Duan XL; Gu JL; Zhao CL; Zhu J; Wu YH; Wu DP; Hu JD; Huang H; Jiang M; Li J; Hou M; Wang C; Shao ZH; Liu T; Hu Y; Huang XJ
Zhonghua Xue Ye Xue Za Zhi; 2016 Mar; 37(3):177-82. PubMed ID: 27033752
[TBL] [Abstract][Full Text] [Related]
7. CD34+ selection and the severity of oropharyngeal mucositis in total body irradiation-based allogeneic stem cell transplantation.
Anand A; Anandi P; Jain NA; Lu K; Dunavin N; Hourigan CS; Le RQ; Chokshi PD; Ito S; Stroncek DF; Sabatino M; Barrett AJ; Battiwalla M
Support Care Cancer; 2016 Feb; 24(2):815-822. PubMed ID: 26190358
[TBL] [Abstract][Full Text] [Related]
8. Leptotrichia trevisanii sepsis after bone marrow transplantation.
Schrimsher JM; McGuirk JP; Hinthorn DR
Emerg Infect Dis; 2013 Oct; 19(10):1690-1. PubMed ID: 24047561
[No Abstract] [Full Text] [Related]
9. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
10. Treatment-related mortality and graft-versus-leukemia activity after allogeneic stem cell transplantation for chronic lymphocytic leukemia using intensity-reduced conditioning.
Dreger P; Brand R; Hansz J; Milligan D; Corradini P; Finke J; Deliliers GL; Martino R; Russell N; Van Biezen A; Michallet M; Niederwieser D;
Leukemia; 2003 May; 17(5):841-8. PubMed ID: 12750695
[TBL] [Abstract][Full Text] [Related]
11. Degree of mucositis and duration of neutropenia are the major risk factors for early post-transplant febrile neutropenia and severe bacterial infections after reduced-intensity conditioning.
Facchini L; Martino R; Ferrari A; Piñana JL; Valcárcel D; Barba P; Granell M; Delgado J; Briones J; Sureda A; Brunet S; Sierra J
Eur J Haematol; 2012 Jan; 88(1):46-51. PubMed ID: 22023368
[TBL] [Abstract][Full Text] [Related]
12. Reduced-intensity conditioning allogeneic transplantation from unrelated donors: evaluation of mycophenolate mofetil plus cyclosporin A as graft-versus-host disease prophylaxis.
Pérez-Simón JA; Martino R; Caballero D; Valcarcel D; Rebollo N; de la Cámara R; de Oteiza JP; Heras I; Calvo MV; Sierra J; San Miguel JF;
Biol Blood Marrow Transplant; 2008 Jun; 14(6):664-71. PubMed ID: 18489992
[TBL] [Abstract][Full Text] [Related]
13. Comparable kinetics of myeloablation between fludarabine/full-dose busulfan and fludarabine/melphalan conditioning regimens in allogeneic peripheral blood stem cell transplantation.
Chunduri S; Dobogai LC; Peace D; Saunthararajah Y; Chen HY; Mahmud N; Quigley J; Hoffman R; Jessop E; Beri R; Rondelli D
Bone Marrow Transplant; 2006 Oct; 38(7):477-82. PubMed ID: 16980995
[TBL] [Abstract][Full Text] [Related]
14. MTX or mycophenolate mofetil with CsA as GVHD prophylaxis after reduced-intensity conditioning PBSCT from HLA-identical siblings.
Piñana JL; Valcárcel D; Fernández-Avilés F; Martino R; Rovira M; Barba P; Martínez C; Brunet S; Sureda A; Carreras E; Sierra J
Bone Marrow Transplant; 2010 Sep; 45(9):1449-56. PubMed ID: 20140024
[TBL] [Abstract][Full Text] [Related]
15. Study of kidney function impairment after reduced-intensity conditioning allogeneic hematopoietic stem cell transplantation. A single-center experience.
Piñana JL; Valcárcel D; Martino R; Barba P; Moreno E; Sureda A; Vega M; Delgado J; Briones J; Brunet S; Sierra J
Biol Blood Marrow Transplant; 2009 Jan; 15(1):21-9. PubMed ID: 19135939
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
